$CBDL CBD Life Sciences, Inc. (CBDL) Debuts Kratom for

New Post Public Reply Private Reply Replies (0) Message Board
louied91
573
$CBDL CBD Life Sciences, Inc. (CBDL) Debuts Kratom for Treatment of Pain and Opioid Withdrawal

https://www.accesswire.com/667804/cbd-life-sc...withdrawal

SCOTTSDALE, AZ / ACCESSWIRE / October 13, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is yet again expanding its product line with Kratom, which is an outstanding addition to the already stacked list of products.

CBD Life Sciences Inc. is currently working with various kinds of Kratom based upon certain specific benefits. This product will be coming live to the LBC website along with eBay, Amazon, and Alibaba within a couple of weeks. The jar will contain 75 capsules and each capsule will contain 500MG. President & CEO Lisa Nelson states "By adding this product to our shelves, it will open up doors to many different kinds of customers and it is becoming more and more known, so I think we got our hands on it at the exact right time!" Lisa Nelson also states, "As a medicine, kratom is used for anxiety, cough, depression, diabetes, diarrhea, high blood pressure, pain, to improve sexual performance, and to lessen symptoms of opiate withdrawal."

What is Kratom?

Kratom is the name of a tree from the coffee family native to Southeast Asia. Also known as mitragyna speciosa, it is grown in Thailand, Malaysia, and Indonesia. Its leaves are dried and used to make tea or encapsulated and sold as a supplement. Kratom leaves can also be smoked like tobacco. The most common uses of it are to relieve pain, depression, and opioid addiction. The two most active compounds found in kratom, mitragynine and 7-hydroxymitragynine, work on opioid receptors, but with fewer side effects. Kratom has been used for hundreds of years in Asia as a natural home remedy. Traditionally, it has been used to treat Fatigue, Pain, Diarrhea, and Muscle Cramps.

Survey

A 2015 study in Thailand that reported that people in Asia have been using kratom successfully to treat opioid addiction for decades renewed interest among researchers in the U.S.

For the current survey, a company and their team enrolled 2,798 people to complete an online survey on their use of kratom. They recruited participants online and through social media, as well as through the AKA. Overall, users were mostly white, educated, and middle-aged. Some 61% of users were women, and 90% were white. About 6% reported being multiracial, 1.5% reported being Native American or Hawaiian, 0.5% reported being Asian and 0.4% said they were African American. Participants were an average age of 40. About 84% of participants reported having at least some college education.

Of these participants, 91% reported taking kratom to alleviate pain on average a couple times a day for back, shoulder and knee pain, 67% for anxiety and 65% for depression. About 41% of survey responders said they took kratom to treat opioid withdrawal, and of those people who took it for opioid withdrawal, 35% reported going more than a year without taking prescription opioids or heroin.

As part of the survey, participants completed a Substance Use Disorder Symptom checklist to assess whether their use qualified as a substance use disorder according to the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition guidelines. Fewer than 3% of responses met the criteria for moderate or severe substance use disorder for abusing kratom, but about 13% met some criteria for kratom-related substance use disorder. This is comparable to about 8%-12% of people prescribed opioid medications who became dependent, according to statistics from the U.S. National Institute for Drug Abuse (NIDA).

CBD Life Sciences Inc. is getting close to its 3rd retail location along with a recreational marijuana facility. This will be significant as far as expansion and revenue go and CBD Life Sciences Inc. will keep the public informed moving forward.

The number of benefits CBD has is tremendous! These benefits may help with behavioral/neurological complications such as ADD/ADHD, anxiety, autism, bipolar, OCD, PTSD, epilepsy, Parkinson's, osteoporosis, and ALS. CBD may also benefit pain management that can stem from headaches/migraines, arthritis, cramps, spinal injuries, and fibromyalgia. CBD has been found to also have gastrointestinal benefits with gastro-disorders and complications such as anorexia, cachexia, Crohn's, diabetes, and nausea. Physical complications/disorders such as muscular dystrophy and even immune system-based deficiencies and other complications such as cancer and hypertension even our bodies way and ability to maintain homeostasis have all been said to benefit from CBD.

CBD Life Sciences Inc. (CBDL) Stock Research Links

CBDL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cloud Software Group Amends $2B Cash Tender Offer

Updated Category News Views 71

Cloud Software Group is stirring the pot with an amendment that'll have bondholders looking twice at their portfolios. On November 3, 2026, the company announced a tweak to its cash tender offer, bumping up the payment for its 9.00% Senior Secured Second Lien Notes due 2029. The payout now jumps from $1,017.50 to $1,022.50 for each $1,000 of principal. If you're holding...

Continue Reading
ACLM and eClinicalWorks Expand Lifestyle Medicine Reach

Updated Category News Views 92

Changing the Game with Lifestyle Medicine When it comes to healthcare, you're always going to have the skeptics grousing about the old ways. But what happens when you take an old idea and turbocharge it with modern tech? That's where the American College of Lifestyle Medicine (ACLM) and eClinicalWorks step in. They’re throwing a new wrench into the electronic health...

Continue Reading
STVN's GLP-1 Fumble Sparks Shareholder Scrutiny

Updated Category News Views 35

The Storm Hits Stevanato: GLP-1 Blues Well, ain't this a fine pickle for Stevanato Group S.p.A. (NYSE:STVN). November 3, 2026, turned into quite the ride for those holding STVN shares. A tough third-quarter report dropped like a ton of bricks, driving the shares down after they coughed up a lower outlook for GLP-1 volumes in 2027. If you've been in the game long enough,...

Continue Reading
Tamagotchi Turns 30: Roblox Event Connects Worlds

Updated Category News Views 17

A New Chapter for an Old Favorite Dust off your digital pets, folks! Tamagotchi is not just a thing of the past. It's busting out of its shell to celebrate a big 3-0 with a splash—and get this—on Roblox. Who would've thought a plastic egg with pixels would still be out there thriving in the ether of childhood nostalgia three decades later? But it is, and it’s taking...

Continue Reading
ROBOTWORLD 2026: AI Reshapes Industrial Horizons

Updated Category News Views 48

A Grand Gathering of Robotics Minds Walking into KINTEX, Seoul's suburban behemoth of an exhibition center, you'll find a buzz that rivals the excitement of a stock floor on earnings day. It's ROBOTWORLD 2026, a stage set for tech titans and ambitious startups alike, all throwing in their chips on AI and robotics. From November 4th to 7th, 402 companies hailing from 17...

Continue Reading
3M's Huge Settlement: Navigating A Looming Legal Fog

Updated Category News Views 94

The latest chapter in 3M’s legal saga reads like a courtroom drama, but this time, the company's shelling out big bucks to sidestep prolonged courtroom battles. They're committing to a $5.8 billion payout over several years, aiming to put a lid on a massive batch of PFAS-related lawsuits. It’s like they’re cleaning the spill with a velvet mop, but the trick is...

Continue Reading
DarioHealth Taps Palumbo to Drive Healthcare Evolution

Updated Category News Views 0

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Continue Reading
VAB's Pharma Ad Guide: Emerging Trends and Insights

Updated Category News Views 191

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Continue Reading
SWFI's I20 Summit Spotlights 3,000 Promising Start-Ups

Updated Category News Views 101

Spotlight on Emerging Titans: The Future 100 Watchlist The Sovereign Wealth Fund Institute is rattling the investment cages with their latest stunt, the 'Future 100 Watchlist.' Hot off the press, this list is parading nearly 3,000 start-ups that are biting at the heels of future success. It's high stakes and higher hopes between December 11-16 at Miami's I20 Summit, where...

Continue Reading
Compass Faces Securities Fraud Suit: Deadline Looms

Updated Category News Views 45

Compass's Legal Rumble: Shareholders Take Note You know there’s trouble when a firm’s every effort at glassy-eyed optimism is slapped with a lawsuit. We've seen this song and dance far too often, and now Compass, Inc. (NYSE: COMP) takes center stage. Schall, Brown & Schwartz LLP is rallying the troops for a knock-down-drag-out class action lawsuit, accusing Compass of...

Continue Reading
s of Cautious Optimism - Continue Reading" aria-label="Continue reading: Farmer Sentiment Rises, Hints of Cautious Optimism"> Continue Reading